Home › Funds › T. Rowe Price › Health Care ETF
Fund family: T. Rowe Price · Filed by T. Rowe Price Exchange-Traded Funds, Inc. (CIK 1795351) · SEC series S000092023
Ticker: TMED (C000259933)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 812 with, 12 against, 0 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 2 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as T. Rowe Price’s manager page (244,024 ballot items across 112 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | T. Rowe Price | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 92.5% | 770 | 93.7% | 208,710 |
| Backed environmental and social shareholder proposals at US companies | n/a | 3 | 2.6% | 3,333 |
Each ballot item this fund voted is set against the votes of the other T. Rowe Price funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most T. Rowe Price funds on 30 items (4.1% of the 733 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most T. Rowe Price funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 2026-06-12 | Election of Directors: Christine A. Poon | Against | FOR — 25 of 25 T. Rowe Price funds | Against | Elected, 76.8% support |
| Regeneron Pharmaceuticals, Inc. | 2026-06-12 | Election of Directors: Craig B. Thompson, M.D. | Against | FOR — 25 of 25 T. Rowe Price funds | Against | Elected, 79.3% support |
| Stryker Corporation | 2026-05-06 | Election Directors: Emmanuel P. Maceda | Against | FOR — 28 of 30 T. Rowe Price funds | Against | Elected, 81.9% support |
| Thermo Fisher Scientific Inc. | 2026-05-20 | An advisory vote to approve named executive officer compensation. | Against | FOR — 36 of 41 T. Rowe Price funds | Against | Not approved, 31.8% support |
| Natera, Inc. | 2026-06-11 | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this noti | For | WITHHOLD — 27 of 30 T. Rowe Price funds | For | Passed (calculated), 87.1% support |
| Natera, Inc. | 2026-06-11 | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this noti | For | WITHHOLD — 27 of 30 T. Rowe Price funds | For | Passed (calculated), 84.7% support |
| Natera, Inc. | 2026-06-11 | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this noti | For | WITHHOLD — 27 of 30 T. Rowe Price funds | For | Passed (calculated), 87.1% support |
| Natera, Inc. | 2026-06-11 | To elect three directors named in the proxy statement accompanying this notice to serve as Class II directors until the annual meeting of stockholders held in 2029 and until their successors are duly elected and qualified, and to elect one director named in the proxy statement accompanying this noti | Withhold | FOR — 27 of 30 T. Rowe Price funds | Against | Passed (calculated), 98.3% support |
| Regeneron Pharmaceuticals, Inc. | 2026-06-12 | Election of Directors: Joseph L. Goldstein, M.D. | Against | FOR — 22 of 25 T. Rowe Price funds | Against | Elected, 70.1% support |
| Eli Lilly and Company | 2026-05-04 | Shareholder Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. | For | AGAINST — 33 of 40 T. Rowe Price funds | Against | Not approved, 33.7% support |
| Bruker Corporation | 2026-05-21 | Election of four Class II directors to serve for a three-year term expiring in 2028: John J. (Jack) Phillips | Withhold | FOR — 5 of 5 T. Rowe Price funds | Against | Elected, 98.6% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | 2 wordings Election of Class I Directors to serve until the 2029 annual meeting of stockholders or until their successor has been duly elected and qualified or until their earlier resignation or removal: G. Clare Kahn, Ph.D. | Withhold | FOR — 8 of 9 T. Rowe Price funds | Against | Passed (calculated), 99.4% support |
| Stoke Therapeutics, Inc. | 2026-06-03 | To approve, on an advisory basis, the compensation of the Company's named executive officers. | Against | FOR — 10 of 12 T. Rowe Price funds | Against | Passed (calculated), 72.9% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Ian Clark | Withhold | FOR — 16 of 22 T. Rowe Price funds | Against | Elected, 65.0% support |
| Guardant Health, Inc. | 2026-06-17 | Election of Class II Directors: Manuel Hidalgo Medina | Withhold | FOR — 16 of 22 T. Rowe Price funds | Against | Elected, 75.5% support |
| Biogen Inc. | 2026-06-09 | 3 wordings Election of Directors. To elect the 10 nominees identified in the accompanying Proxy Statement to our Board of Directors to serve for a one-year term extending until our 2027 annual meeting of stockholders and their successors are duly elected and qualified: Susan K. Langer | For | AGAINST — 10 of 14 T. Rowe Price funds | For | Passed (calculated), 85.3% support |
| Agios Pharmaceuticals, Inc. | 2026-06-18 | To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Cynthia Smith | Withhold | FOR — 5 of 6 T. Rowe Price funds | Against | Passed (calculated), 68.3% support |
| Agios Pharmaceuticals, Inc. | 2026-06-18 | To elect each of the three Class I director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Rahul Ballal, Ph.D. | Withhold | FOR — 5 of 6 T. Rowe Price funds | Against | Passed (calculated), 87.1% support |
| Caris Life Sciences, Inc. | 2026-06-04 | Election of Directors: Peter M. Castleman | Withhold | FOR — 8 of 11 T. Rowe Price funds | Against | Elected, 76.3% support |
| West Pharmaceutical Services, Inc. | 2026-05-04 | Shareholder Shareholder proposal regarding an independent Board Chair policy. | For | AGAINST — 9 of 13 T. Rowe Price funds | Against | Not approved, 46.4% support |
| Alnylam Pharmaceuticals, Inc. | 2026-05-20 | To elect the following nominees as Class I directors of Alnylam: Stuart A. Arbuckle | Against | FOR — 10 of 15 T. Rowe Price funds | Against | Elected, 95.8% support |
| Ionis Pharmaceuticals, Inc. | 2026-06-04 | Election of Directors: Joan E. Herman | For | AGAINST — 13 of 22 T. Rowe Price funds | For | Passed (calculated), 96.4% support |
| Crinetics Pharmaceuticals, Inc. | 2026-06-18 | To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Caren Deardorf | Withhold | FOR — 10 of 16 T. Rowe Price funds | Against | Passed (calculated), 75.7% support |
| Crinetics Pharmaceuticals, Inc. | 2026-06-18 | To elect three directors to serve as Class II directors for a three-year term to expire at the 2029 annual meeting of shareholders: Stephanie S. Okey, M.S. | Withhold | FOR — 10 of 16 T. Rowe Price funds | Against | Passed (calculated), 74.5% support |
| Dianthus Therapeutics, Inc. | 2026-05-21 | To elect Class II directors to our Board of Directors, to serve until the 2029 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal: Anne McGeorge | Withhold | FOR — 9 of 16 T. Rowe Price funds | Against | Passed (calculated), 80.6% support |
| Company | Meeting | Item | This fund | Most T. Rowe Price funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Kodiak Sciences Inc. | 2026-06-02 | Elect three Class II directors nominated by our board and named in this proxy statement: Charles A. Bancroft | Withhold | FOR — 8 of 15 T. Rowe Price funds | Against | Elected, 78.7% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: David Schenkein, M.D. | Withhold | FOR — 8 of 15 T. Rowe Price funds | Against | Elected, 73.5% support |
| Denali Therapeutics Inc. | 2026-06-03 | ELECTION OF DIRECTORS: Jennifer Cook | Withhold | FOR — 8 of 15 T. Rowe Price funds | Against | Elected, 60.9% support |
| Sarepta Therapeutics, Inc. | 2026-06-04 | To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Michael Chambers | For | AGAINST — 3 of 4 T. Rowe Price funds | For | Elected, 97.4% support |
| NovoCure Limited | 2026-06-03 | The approval of our amended and restated 2024 Omnibus Incentive Plan. | For | AGAINST — 2 of 3 T. Rowe Price funds | For | Approved, 50.3% support |
Download all 30 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 89.1% of this fund’s 824 such votes could be given a sector; the other 90 (10.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 644 | 11 | 1.7% |
| Industrials | 73 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 520 | 0 |
| Audit-related | 98 | 0 |
| Say-on-Pay | 88 | 0 |
| Compensation | 46 | 1 |
| Corporate Governance | 45 | 8 |
| Capital Structure | 22 | 0 |
| Extraordinary Transactions | 8 | 0 |
| Shareholder Rights and Defenses | 4 | 0 |
| Other Social Issues | 3 | 2 |
| Environment or Climate | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $4M | 10 | 2 |
| UnitedHealth Group Incorporated | June 1, 2026 | $2M | 12 | 1 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $1M | 13 | 0 |
| Humana Inc. | April 16, 2026 | $810,702 | 14 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $799,524 | 15 | 3 |
| Abbott Laboratories | April 24, 2026 | $789,197 | 16 | 0 |
| Danaher Corporation | May 5, 2026 | $623,598 | 14 | 0 |
| Waters Corporation | May 21, 2026 | $446,259 | 13 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| April 16, 2026 | Humana Inc. | The stockholder proposal requesting shareholder approval requirement for excessive golden parachutes, if properly presented at the meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 4, 2026 | West Pharmaceutical Services, Inc. | Shareholder proposal regarding an independent Board Chair policy. Shareholder proposal | For | Against |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | Against | For |
| April 30, 2026 | Boston Scientific Corporation | Stockholder proposal titled "Give Shareholders the Ability to Call for a Special Shareholder Meeting." Shareholder proposal | Against | For |
| May 12, 2026 | IDEXX Laboratories, Inc. | Shareholder Proposal to Give Shareholders the Ability to Call for a Special Shareholder Meeting (Proposal Six). Shareholder proposal | Against | For |
| May 5, 2026 | Bristol-Myers Squibb Company | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposal | Against | For |
835 ballot items at 100 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Health Care ETF (TMED) voted at 100 shareholder meetings of 97 companies, on 835 ballot items in all. Where management made a recommendation, the fund followed it on 98.5% of the items and voted against it 12 times. Its most frequent area of disagreement was corporate governance (8 of its votes against management). It voted on 13 shareholder proposals. It voted FOR the board's own proposals less often than T. Rowe Price's funds as a whole (92.5% against 93.7%). It voted differently from most T. Rowe Price funds on 30 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of T. Rowe Price’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.